UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics™), today announced that Bill Lundberg, M.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on Tuesday, November 17, 2020 at 14:40 p.m. GMT/9:40 a.m. ET.
A live webcast of the presentation will be available on the Investors page of the Company’s website, http://www.merus.nl/. An archived presentation will be available on the Merus website for a limited time.
About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website, www.merus.nl and https://twitter.com/MerusNV.
CONTACT: Investor and Media Inquiries: Jillian Connell Merus N.V. Investor Relations and Corporate Communications 617-955-4716 j.connell@merus.nl
Vancouver, British Columbia--(Newsfile Corp. - March 28, 2024) - CENTR Brands Corp. (CSE: CNTR) (FSE:…
BOCA RATON, FL / ACCESSWIRE / March 28, 2024 / Haven Health Care Services, a…
BOULDER, CO / ACCESSWIRE / March 28, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global…
JACKSONVILLE, FL / ACCESSWIRE / March 28, 2024 / LFTD Partners Inc. ("LFTD Partners" or…
Unify Medical, Inc., a privately held, smart surgical visualization technology company, announced the appointment of…
Texas-based specialty practice chooses eClinicalWorks Cloud EHR to increase automation, streamline workflows, and enhance patient…